Moving forward, validating whether LRRK2 inhibition can similarly dampen microglial activation in α-syn–driven models will be critical for corroborating our therapeutic strategy.the simplicity of these models limits their ability to recapitulate the complexity of human Parkinson’s disease. Here, LRRK2 is linked to Parkinson disease.